Background: This phase HI study was carried out to verify whether a kinetic recruitment induced with low doses of diethylstilbestrol (DES) could increase the antitumor activity of chemotherapy in patients with advanced breast cancer.
Introduction
The capacity of estrogens to recruit resting breast cancer cells has been proven in experimental models as well as in patients; experimental data indicate that the l in vivo' administration of estrogens directly stimulates the proliferative activity of tumor cells; moreover, these hormones are able to modulate the kinetic response of breast cancer cells to other growth factors [1] [2] [3] [4] , and this might explain why even estrogen receptor-negative tumors can proliferate following estrogenic stimulation [3, 5] . The 'kinetic induction' could ameliorate the killing efficacy of antiblastic drugs administered at the time of estrogen-induced tumor cell recruitment. Several clinical trials have been performed in an attempt to exploit the increased killing efficacy of chemotherapy preceded by estrogenic recruitment in locally advanced and metastatic breast cancer. These studies have shown that estrogenic recruitment before chemotherapy is feasible with acceptable toxicity, and they have reported interesting response rates and prolonged survivals [5] [6] [7] ; unfortunately these promising results were not confirmed when cytokinetic chemotherapy was compared with conventional chemotherapy in randomized trials [8] [9] [10] [11] [12] . In our previously published trial we observed a greater myelotoxicity with reduced dose-intensity in the cytokinetic arm with estrogenic recruitment [13] ; this more severe toxicity was attributed to the different schedules of drugs employed in the cytokinetic arm.
On these premises a second randomized trial was started in 1987; in this study the schedule of antiblastic drugs was identical in the two treatment arms. This study was closed to accrual in 1990 when 258 metastatic breast cancer patients had been enrolled. This paper reports the results of this second multicenter randomized trial.
Patients and methods
Female patients with metastatic breast cancer were randomized to receive CEF (cyclophosphamide 600 mg/sqm; epidoxorubicin 60 mg/sqm and 5-fluorouraci] 600 mg/sqm) every 21 days or the same regimen preceded by diethylstilbestrol (DES) 1 mg orally daily for 3 days; the three drugs were administered in the two arms on the same day.
Eligibility criteria were: histologically-proven breast cancer, measurable metastatic disease, age <70 years, Eastern Cooperative Oncology Group (ECOG) performance status <2, and no previous chemotherapy for metastatic disease. Adjuvant chemotherapy, not containing anthracycUnes, was permitted if terminated at least 6 months before relapse; prior hormonal adjuvant therapy was allowed. Patients were excluded if they had any medical contraindication to chemotherapy, and verbal informed consent was required. Patients were not stratified before randomization and the impact of the following prognostic factors was retrospectively analyzed: menopausal status, prior adjuvant chemotherapy, prior adjuvant hormonal therapy, sites of disease.
At entry all patients uderwent a physical examination with complete blood cell count, chemistry profile, EKG, chest X-ray, radionuclide bone scan and liver ultrasound. Blood cell counts were repeated immediately before each subsequent course (on day 21) and chemotherapy was delayed until recovery if WBCs were < 3.500/ul and/or platelets were < 100.000/uI.
Patients were treated until progression or, if responsive, for a maximum of 10 courses, and thereafter observed in unmaintained remission. Patients were assessed before each cycle and target lesions were evaluated every two cycles.
Response to treatment was defined as follows: a complete response (CR) was the complete disappearance of all known lesions for at least 3 months. A partial response (PR) was considered a reduction >50% in the sum of the product of the two largest diameters of each target lesion for at least 3 months. Stable disease (SD) was defined as a <50% reduction and no more than 25% increase in size of any lesion with no new metastases appearing. Any increase >25% of target lesions and/or the appearance of new metastases was considered as progressive disease (PD).
Statistical analysis
The patients were centrally randomized by phone call to the clinical trial office in the National Institute for Cancer Research. A balanced randomization list was prepared for each cooperative institution. Survival and progression-free survival curves were calculated according to Kaplan and Meier {14]. The significance of differences between curves was determined by log-rank test [15] . Response rates and toxicities were compared by a chi-square test Toxicities were reported according to the WHO recommendations.
Results
Between November 1985 and January 1990 two hundred fifty-eight patients were randomized by 10 institutions; four patients were ineligible (prior chemotherapy for metastatic breast cancer) and 24 were not evaluable for response: 20 because of treatment refusal (10 in each arm) and four who were lost to follow-up. All randomized patients are included in the survival and progression-free survival curves.
The characteristics of the patients are summarized in Table 1 . The toxicities of the two treatment arms are reported in Table 2 ; while WBC counts at nadir were not routinely performed, a grade 2 or more leukopenia requiring a delay of chemotherapy was observed in 22.7% of CEF courses and 34.2% of DES-CEF courses (P -0.007); this caused a reduction in the dose intensity of the cytokinetic arm: 82% of the patients in the standard arm received 0.85 or more of the planned dose intensity versus 67% of the patients in the DES group (Table 3) ; this difference is statistically significant (P= 0.01). Twenty-three episodes of febrile neutropenia have been observed (10 in the CEF, 13 in the DES-CEF arm). Except for leukopenia, no differences in toxicity were observed between the two arms.
The overall response rates are reported in Table 4 : 51.3% of patients in the CEF arm and 49.6% of DES-CEF patients experienced an objective response; the complete response rates were 12.2% and 14.8% in the CEF and DES-CEF arms, respectively: this difference is not statistically significant. At the time of the present analysis 88% of the patients have died and 97% have shown progressive disease. Median survivals were 17.3 and 20 months (P = 0.7), and median progression-free survivals 9.4 and 11 months in the CEF and DES-CEF arms, respectively (P -0.39); these differences are not statistically significant (Figures 1 and 2 ).
Discussion
Here we report the results of our second cooperative randomized trial designed to define the role of estrogenic recruitment before chemotherapy in metastatic breast cancer patients. In our previous study no differences in response rate, overall survival or progression-free survival between the two arms were observed; however, some subsets of DES-CEF-treated patients experienced a higher CR rate despite a greater myelotoxicity, which was attributed to the different schedule of antiblastic drugs in the cytokinetic arm [9] . Two other randomized trials assessing the role of estrogenic recruitment in metastatic breast cancer have been published. In the study from the EORTC no differences were observed in response rate or survival between chemotherapy preceded by estrogenic recruitment and chemotherapy alone [10] . In the study by Ingle et al. [11] , the patients treated with DES-CMF experienced a statistically significantly higher response rate (calculated after adjustment for site of predominant disease) than patients receiving CMF alone; unfortunately there was no advantage in terms of time to progression or overall survival.
The overall results of the present trial demonstrate no differences in response rates (51.3% overall response for conventional chemotherapy vs. 49.6% for experimental arm), survival (median survival 17.3 months for CEF and 20 months for DES-CEF) or progression-free survival (median 9.4 months for CEF and 11 months for DES-CEF). The only significant difference is the incidence of grade 2 or more leukopenia on day of recycle which was significantly higher in the arm with estrogenic recruitment (34.2% vs. 22.7%, P-0.007). This finding was already observed in our first randomized study in metastatic breast cancer patients [9] . The more severe leukopenia of the DES chemotherapy could be attributable in part to the fact that in the experimental arm the haematological controls were performed 3 days earlier (before starting DES); however, other reasons can not be excluded; in particular, DES might increase the sensitivity of bone marrow progenitor cells to chemotherapy either through a direct kinetic effect or by the action of different growth factors. This resulted in a limited but significant reduction in the dose intensity of antiblastic drugs (Table 3) . It is quite unlikely, however, that such a limited reduction in the dose intensity might have compromized the efficacy of chemotherapy.
Including the present study, five randomized trials on estrogenic recruitment with a total of about 900 patients have been completed in metastatic breast cancer, and no significant advantage in response rate, progression-free survival or survival has been documented [8] [9] [10] [11] .
A possible explanation for the lack of positive clinical results despite the sound experimental evidence is that the proportion of genetically chemoresistant cancer cells is very high in metastatic breast cancer. We recently published a randomized study with estrogenic recruitment in locally advanced breast cancer, a potentially curable disease in which the proportion of genetically chemoresistant cancer cells is lower; here again the attempt to increase chemosensitivity with estrogens has not met expectations [12] . The discrepancy between the experimental data, which are consistent with the capacity of estrogens to stimulate breast cancer cell growth in vivo, and the deceptive clinical results might be explained by the low proportion of cancer cells which are induced to proliferate [2, 3, 5] . The mitogenic stimulus could be increased by combining estrogens with growth hormone or estrogens plus polyamine manipulation [16, 17] . A possible alternative explanation derives from the new information about the biology of breast cancer; it is now accepted that growth factors have an autocrine activity only in a certain subset of breast cancer tumors and many human breast cancers become growth factor-autonomous [18] .
In conclusion, this and the other trials indicate that, at present, there is no clinical use for estrogenic recruitment. The attempt to manipulate the proliferation of cancer cells should take into account the new data on the mechanisms which regulate the growth of breast cancer in vivo.
